The Revita GLP-1 study found less weight regain after stopping tirzepatide. GLP-1 is a gut hormone involved in appetite. Both groups regained weight on average.
The procedure may eventually offer another maintenance option. It hasn't established that one treatment keeps weight off for good, and it remains investigational in the United States.
As of October 29, 2026, the day this article was written, Fractyl Health's October 16 announcement reports a successful six-month result. The pivotal study's one-year test is still ahead. These are company-reported findings, not a peer-reviewed publication.
What the Revita GLP-1 results actually measured
REMAIN-1 enrolled 308 adults with obesity who had lost at least 15% of their weight on tirzepatide. They stopped the medicine, then were assigned by chance to Revita or a sham procedure, an imitation without the active treatment. Diet and lifestyle counseling continued in both groups.
Revita uses duodenal mucosal resurfacing: heat treatment of the lining of the first part of the small intestine. An endoscope, a flexible tube passed through the mouth, guides the procedure. Earlier research, including REVITA-2 in Gut, 2022, studied it for type 2 diabetes. That earlier trial didn't establish weight maintenance after stopping tirzepatide.
The new study asked whether treating that lining could reduce regain after medication ended. It did not compare Revita with continuing tirzepatide.
| Six-month result reported by Fractyl | Revita | Sham |
|---|---|---|
| Adjusted average body-weight regain | 5.1% | 8.2% |
| Approximate share of earlier weight loss retained | 80% | 67% |
The SEC-filed release reports p=0.0023, a statistical measure supporting a difference between groups. The percentages are adjusted estimates from the study's analysis, not a promise about an individual's outcome.
For someone already taking tirzepatide, this is evidence about a possible future option after stopping. It doesn't replace evidence about staying on treatment.
What this means for someone considering stopping
The reason this matters is familiar: losing weight and maintaining that loss are different parts of care. Removing an active treatment can change what happens next, even when lifestyle support continues.
In SURMOUNT-4, published in JAMA in 2024, people switched off tirzepatide gained 14.0% of their weight at the switch over the following year. Those continuing it lost another 5.5%. The SURMOUNT-4 results explain that trial's design and limits.
Those numbers cannot be set beside REMAIN-1 as a contest between medication and procedure. The studies followed different people for different lengths of time. A direct comparison would need its own trial.
The practical question is broader than whether a procedure might someday help. Continuing treatment, reducing it or stopping involves the reason for treatment, side effects, medical history and follow-up. Our guide to what happens after stopping tirzepatide covers that conversation.
Does the finding apply after semaglutide?
REMAIN-1 used tirzepatide before the procedure. Its result doesn't establish the same benefit after semaglutide, even though both medicines work on appetite-related signals involving GLP-1.
Semaglutide has its own withdrawal evidence. In the STEP 1 extension, Diabetes, Obesity and Metabolism, 2022, participants regained about two-thirds of their earlier loss over a year. Both medication and the trial's lifestyle intervention had ended.
That finding helps explain the interest in maintenance treatments. It doesn't show that Revita works equally well after every weight-loss medicine. The guide to stopping semaglutide separates its evidence from tirzepatide's.
What the safety report says
As of October 29, 2026, the day this article was written, Fractyl's October 16 safety presentation covers data through September 24. The release says there were “no device- or procedure-related serious adverse events.”
The detailed table makes a distinction. None were judged probably or definitely related. Two serious events in one Revita participant were classified as possibly related: digestive-tract bleeding and blood-loss anemia, too few red blood cells after bleeding. The company also noted painkiller use and no duodenal bleeding on examination.
Common related symptoms included throat pain, nausea and abdominal pain. A short-term safety report also cannot settle uncommon risks or what happens years later.
What the headline doesn't establish
Keeping about 80% of earlier weight loss is an average result. It doesn't mean 80% of people avoided regain. Both groups gained weight on average.
The two main outcomes were chosen in advance. One compared regain at six months. The other asks how many Revita participants remain at least 5% below their pre-tirzepatide weight at one year. Its preset goal is more than half the treated group meeting that mark. Clearing the first test doesn't settle the second.
The participants also had no type 2 diabetes and had already responded well to tirzepatide. The result cannot automatically extend to people with diabetes, smaller initial losses or different medical histories.
What a prescribing conversation covers now
The procedure's early result leaves today's medication decisions with the patient and prescriber. A maintenance plan can include a discussion of appetite, weight trends, blood sugar where relevant and tolerability. REMAIN-1 doesn't provide a medication taper or a reason to stop on a particular date.
Compounding means a pharmacy prepares medicine for an individual patient. Tirzepatide and semaglutide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from an FDA-approved product. The formulations offered here are not FDA-approved.
The FDA's compounding Q&A, current as of September 16, 2025, says FDA doesn't verify compounded drugs' safety, effectiveness or quality before they are marketed. Trial results for branded medicines cannot establish identical results for a pharmacy's preparation.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
What to watch next
As of October 29, 2026, the day this article was written, Fractyl plans a De Novo submission late in the last quarter of 2026. That is an FDA pathway for reviewing certain new devices. Its October 16 release anticipates the pivotal one-year results in the first quarter of 2027. Those are company plans, not completed milestones.
Revita is not FDA-authorized for U.S. marketing. Its Breakthrough Device designation supports development and review; the FDA's program explanation distinguishes that process from marketing authorization.
The next useful evidence is whether the difference lasts, alongside the full safety findings. A future treatment option becomes more useful when its benefits, risks and limits are clearer.
